🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 18 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/03/2009 3,90 4,32 3,84 4,08 +6,25% 12,31% 71.167
13/03/2009 3,54 3,90 3,54 3,84 +16,36% 10,17% 77.567
12/03/2009 3,30 3,84 3,12 3,30 -3,51% 21,82% 100.267
11/03/2009 3,12 3,72 3,12 3,42 -8,06% 19,23% 32.417
10/03/2009 3,72 3,96 3,60 3,72 +3,33% 9,68% 29.017
09/03/2009 3,96 4,14 3,60 3,60 -4,76% 13,64% 40.117
06/03/2009 3,48 3,78 3,48 3,78 +3,28% 8,62% 15.600
05/03/2009 3,72 3,96 3,54 3,66 +1,67% 11,29% 55.083
04/03/2009 3,60 3,66 3,30 3,60 +7,14% 10,00% 25.683
03/03/2009 3,24 3,48 3,24 3,36 +0,00% 7,41% 40.850
02/03/2009 3,66 3,66 3,36 3,36 -6,67% 8,20% 30.367
27/02/2009 4,14 4,14 3,60 3,60 -10,45% 13,04% 29.700
26/02/2009 4,14 4,14 3,72 4,02 +3,08% 10,14% 43.617
25/02/2009 4,14 4,26 3,90 3,90 -8,45% 8,70% 15.600
24/02/2009 3,84 4,50 3,84 4,26 +9,23% 17,19% 31.633
23/02/2009 4,38 4,86 3,66 3,90 -10,96% 27,40% 42.250
20/02/2009 4,62 4,74 4,26 4,38 -8,75% 10,39% 34.967
19/02/2009 5,10 5,64 4,68 4,80 -6,98% 18,82% 19.583
18/02/2009 4,86 5,16 4,86 5,16 +6,17% 6,17% 21.800
17/02/2009 4,80 4,86 4,68 4,86 -3,57% 3,75% 19.650
13/02/2009 5,52 5,52 4,86 5,04 -7,69% 11,96% 28.283
12/02/2009 5,46 5,76 5,16 5,46 -1,09% 10,99% 41.700
11/02/2009 5,58 5,58 5,46 5,52 +0,00% 2,15% 11.417
10/02/2009 5,82 5,88 5,46 5,52 -5,15% 7,22% 48.600
09/02/2009 5,40 5,94 5,34 5,82 +8,99% 11,11% 70.400
06/02/2009 5,22 5,82 5,22 5,34 +4,71% 11,49% 68.300
05/02/2009 5,16 5,40 4,98 5,10 -2,30% 8,14% 29.133
04/02/2009 4,50 5,40 4,50 5,22 +11,54% 20,00% 64.483
03/02/2009 4,44 5,10 4,32 4,68 +2,63% 17,57% 31.600
02/02/2009 5,40 5,40 4,50 4,56 -12,64% 16,67% 109.667